VAXCYTE, INC.

Biotech · Private

Novel influenza A vaccine based on HA stem trimer antigen produced via cell-free expression technology

Grants
$196K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
40
7 granted · 33 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of a Universal Influenza Vaccine Produced by Cell-Free Protein Synthesis$196,063
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2160PSYENCE BIOMEDICAL LTD.—$2.0M
2161MITORAINBOW THERAPEUTICS, INC.——
2162Avanti Biosciences Inc——
2163VAXCYTE, INC.——
2164Arctus Biosciences——
2165NEMALIFE INC——
2166PRIME LABS INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 7 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.